Faculty Start-ups


Nicholas Kotov Ph.D., Professor of Chemical Engineering, Associate Professor of Biomedical Engineering and Associate Professor of Materials Science and Engineering

3D-Biomatrix provides a 3-D environment for culturing cells that offers a drug-testing platform mimicking human organs. Called a "human in a test-tube," this platform tests drugs' efficacy and side-effects more effectively and consistently than current 2-D substrates. The optically transparent platform also has applications in cell expansion, tissue engineering, and cell imaging.

Biomatrix Photonics LLC

Steven Goldstein, Ph.D. Henry Ruppenthal Family Professor, Orthopaedic Surgery and Bioengineering; Professor, Biomedical Engineering; Professor, Mechanical Engineering
Michael Morris, Ph.D. Professor of Chemistry
Blake Roessler, M.D. Associate Professor, Internal Medicine; Associate Professor, Pharmaceutics

Biomatrix Photonics LLC is commercializing a Raman Spectroscopy-based technology to diagnose and monitor the treatment of osteoporosis and connective tissue disorders. Its lead products are based on substantial intellectual property in imaging bone fragility in osteoporosis. Related technologies are being developed to evaluate degenerative conditions in other connective tissues and to monitor regenerative therapies.

Biotectix LLC

David Martin, Ph.D., Karl W. Böer Professor and Chair at University of Delaware; Adjunct Professor at University of Michigan Sarah Richardson-Burns, Ph.D., Senior Research Fellow, Materials Science and Engineering Jeffrey Hendricks, Ph.D., Biotectix (PhD from UM BME)

Formed in 2007, Biotectix LLC grew out of research in Prof. Martin's laboratory on the use of conductive polymers for biocompatible neural electrodes. By applying a thin coating of conductive polymer and biomolecules to the electrodes' surface, he was able to direct the tissue reaction around them while improving electrical transfer across the interface. Biotectix coatings have the potential to improve the performance and longevity of implanted devices like pacemakers, cochlear implants, deep brain stimulators, spinal cord stimulation, and neural recording electrodes. In 2010, Biotectix secured $3 million to prepare its novel conductive polymer technology for human use.


Charles Cain Ph.D. Richard A. Auhll Professor, Engineering, Professor, Biomedical Engineering; Professor, Electrical Engineering & Computer Science;
Brian Fowlkes Ph.D. Professor, Radiology; Professor, Biomedical Engineering
Timothy Hall Ph.D. Assistant Research Scientist, Biomedical Engineering
Zhen Xu Ph.D. Assistant Professor, Biomedical Engineering
William Roberts M.D. Associate Professor, Department of Urology; Associate Professor, Biomedical Engineering

Seeking a surgical option that could combine the optimized results of open surgery with the quick recovery and minimal complications of less-invasive procedures, Charles Cain and Brian Fowlkes discovered that they could use focused sound waves to non-invasively break up tumors and unwanted lesions. They named this tool "Histotripsy". Joining forces with Zhen Xu, Timothy Hall, and urologist William Roberts, they formed HistoSonics to commercialize the technology. The company boasts $11 million in venture financing to develop its clinical prototype and solicit FDA approval. The first clinical application will be benign prostatic hyperplasia; other areas of investigation include thrombolysis (clot breakup), kidney stones, uterine fibroids, breast lesions, and brain tumors.

Incept BioSystems

Shuichi Takayama, Ph.D. Professor, Biomedical Engineering, Macromolecular Science and Engineering
Gary D. Smith, Ph.D. Professor, Molecular & Integrative Physiology, OB/Gyn and Urology

Incept BioSystems develops microscale technologies that provide breakthrough capabilities to treat infertility. Its microfluidic-based technologies improve the in-vitro manipulation, performance, and viability of high-value cells, and its mission is to set the standard for next-generation clinical devices in the Assisted Reproduction Technology (ART) lab. To date, Incept BioSystems has received venture capital, an NIH SBIR grant, and funding from the Michigan Economic Development Corporation.


Shuichi Takayama, Ph.D. Professor, Biomedical Engineering, Macromolecular Science and Engineering
Arlyne Simon, Ph.D. Graduate Student, Macromolecular Science and Engineering
Joshua White, Ph.D. Graduate Student, Biomedical Engineering

PHASIQ is commercializing high quality multiplex immunoassays with unprecedented time- and cost-savings. Our proprietary micropatterned phase separation (MPS™) technology makes PHASIQ the only company that can reliably prevent false negative and false positive signals in multiplex immunoassays. The MPS™ technology is versatile and also has other applications include physiologically-relevant cell-based assays.